ABBISKO CAYMAN DL-00001 Net Assets
ABBISKO CAYMAN DL-00001 net assets. Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) has net assets worth €1.92 Billion EUR (≈ $2.25 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.35 Billion ≈ $2.75 Billion USD) and total liabilities (€430.22 Million ≈ $502.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of ABBISKO CAYMAN DL-00001 to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.92 Billion |
| % of Total Assets | 81.72% |
| Annual Growth Rate | -6.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.78 |
Net Assets of ABBISKO CAYMAN DL-00001 (2021–2025)
Net assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025. This chart illustrates how ABBISKO CAYMAN DL-00001's net assets have evolved over time, based on quarterly financial data. See how leveraged is ABBISKO CAYMAN DL-00001's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual net assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025. For live market cap and overall valuation, see how much is ABBISKO CAYMAN DL-00001 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.92 Billion ≈ $2.25 Billion |
-1.81% |
| 2024-12-31 | €1.96 Billion ≈ $2.29 Billion |
-1.15% |
| 2023-12-31 | €1.98 Billion ≈ $2.32 Billion |
-15.57% |
| 2022-12-31 | €2.35 Billion ≈ $2.74 Billion |
-7.48% |
| 2021-12-31 | €2.54 Billion ≈ $2.96 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABBISKO CAYMAN DL-00001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84364000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ABBISKO CAYMAN DL-00001 Net Assets Breakdown (December 2025)
ABBISKO CAYMAN DL-00001 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.75 Billion | 298.84% |
| Total Equity | €1.92 Billion | 100.00% |
ABBISKO CAYMAN DL-00001 Competitors by Market Cap
The table below lists competitors of ABBISKO CAYMAN DL-00001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NETGEAR Inc
NASDAQ:NTGR
|
$566.41 Million |
|
Orthopediatrics Corp
NASDAQ:KIDS
|
$566.58 Million |
|
Wangli Security & Surveillance Product Co. Ltd
SHG:605268
|
$566.87 Million |
|
Zhejiang Gongdong Medical Technology Co Ltd
SHG:605369
|
$566.90 Million |
|
Rio2 Ltd
V:RIO
|
$566.25 Million |
|
Zhejiang Netsun Co Ltd
SHE:002095
|
$566.18 Million |
|
Guangdong Enpack Packaging Co Ltd
SHE:002846
|
$566.03 Million |
|
Sido Muncul PT
JK:SIDO
|
$565.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABBISKO CAYMAN DL-00001's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,958,336,000 to 1,922,878,000, a change of -35,458,000 (-1.8%).
- Net income of 55,247,000 contributed positively to equity growth.
- Share repurchases of 96,152,000 reduced equity.
- New share issuances of 4,807,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €55.25 Million | +2.87% |
| Share Repurchases | €96.15 Million | -5.0% |
| Share Issuances | €4.81 Million | +0.25% |
| Other Changes | €640.00K | +0.03% |
| Total Change | €- | -1.81% |
Book Value vs Market Value Analysis
This analysis compares ABBISKO CAYMAN DL-00001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.04 | €0.73 | x |
| 2022-12-31 | €3.62 | €0.73 | x |
| 2023-12-31 | €3.06 | €0.73 | x |
| 2024-12-31 | €2.93 | €0.73 | x |
| 2025-12-31 | €2.90 | €0.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABBISKO CAYMAN DL-00001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.03%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.22x
- Recent ROE (2.87%) is above the historical average (-21.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -71.37% | -7979.87% | 0.01x | 1.05x | €-2.06 Billion |
| 2022 | -21.12% | 0.00% | 0.00x | 1.06x | €-730.24 Million |
| 2023 | -21.78% | -2264.34% | 0.01x | 1.07x | €-629.69 Million |
| 2024 | 1.45% | 5.62% | 0.24x | 1.08x | €-167.53 Million |
| 2025 | 2.87% | 9.03% | 0.26x | 1.22x | €-137.04 Million |
Industry Comparison
This section compares ABBISKO CAYMAN DL-00001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABBISKO CAYMAN DL-00001 (8ZD) | €1.92 Billion | -71.37% | 0.22x | $566.33 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more